CAR+ and CAR− T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies

CAR+ and CAR− T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies

Abstract Chimeric antigen receptor (CAR) T cell therapy is effective in treating B cell malignancies, but factors influencing the persistence of functional CAR+ T cells, such as product composition, patients’ lymphodepletion, and immune reconstitution, are not well understood. To shed light on this...

Full description

Bibliographic Details
Main Authors: Raymond Hall Yip Louie, Curtis Cai, Jerome Samir, Mandeep Singh, Ira W. Deveson, James M. Ferguson, Timothy G. Amos, Helen Marie McGuire, Kavitha Gowrishankar, Thiruni Adikari, Robert Balderas, Martina Bonomi, Marco Ruella, David Bishop, David Gottlieb, Emily Blyth, Kenneth Micklethwaite, Fabio Luciani
Format: Article
Language:English
Published: Nature Portfolio 2023-11-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-023-43656-7

Internet

https://doi.org/10.1038/s41467-023-43656-7

Similar Items